FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic...( regardingwhether and when to approve an...),Health

Date:2/19/2008

, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2006. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

For Further Information, Please Contact:

UCB

Antje Witte, Vice-President, Corporate Communications and Investor Relations
Phone: +32.2.559.9414,

antje.witte@ucb-group.com

Eric Miller, Director, U.S. Corporate Communications and Public Relations

Phone: 770-970-8569

eric.miller@ucb-group.com

sanofi-aventis

Susan Brooks, US Communications

Phone: 908-981-6566 Mobile: 201-572-4994

Email: Susan.Brooks@sanofi-aventis.com

XYZAL(R) is a trademark of UCB Group of companies.

'/>"/>

SOURCE sanofi-aventis Copyright©2008 PR Newswire. All rights reserved

5 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. Tourtellotte Solutions Blazes Trail with New Release of Clinical Trial Supply Chain Simulator
7. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
8. Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007
9. Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms
10. Facet Solutions Enjoys Continued Clinical Success With the Anatomic Facet Replacement System (AFRS(TM))
11. Facet Solutions AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing